이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Neuroactive Steroids in Acute Ischemic Stroke (Cortisol)

2017년 8월 7일 업데이트: Sebastian Casas, Hospital Militar Central, Argentina

Changes in Plasma Cortisol, Brain-derived Neurotrophic Factor, and Nitrites in Patients With Acute Ischemic Stroke

Acute ischemic stroke (AIS) represents an economical challenge for health systems all over the globe. Despite increasing knowledge of the pathophysiology of AIS, there is no satisfactory treatment to revert the resulting brain damage. Changes of neuroactive steroids have been found in different neurological diseases. In this regard, the investigators have previously demonstrated that old patients with AIS show changes of plasma cortisol and estradiol concentrations, in that increased steroid levels are associated with a deterioration of neurological status and a worse cognitive decline. The present study assessed in patients with AIS if changes of behavior, brain-derived neurotrophic factor (BDNF) and nitrites (NO-2) (nitric oxide soluble metabolite) bear a relationship with the degree of hypercortisolism. To this purpose, the investigators recruited patients hospitalized at the Central Military Hospital emergency room within the first 24 hours of AIS. Subjects were divided into two groups, each one composed of 40 control subjects and 40 AIS patients, including men and women. The neurological condition was assessed using the NIHSS and the cognitive status with the Montreal Cognitive Assessment (MoCA test). The emotional status was evaluated using the Montgomery-Asberg Depression Rating Scale (MADRS), whereas the Modified Rankin Scale (MRS) was used to determine the functional condition. BDNF and NO-2 plasma levels were measured by ELISA and the Griess reaction method, respectively.

연구 개요

상세 설명

Acute Ischemic Stroke (AIS) is one of the main causes of functional deterioration all over the world. Thus, 26% of patients older than 65 years still show limitations of daily activities 6 months after AIS, and 46% of these patients present cognitive deficiency of variable severity. AIS impose a burden on the way of living of patients and their families' in which depression emerges as a frequent neuropsychiatric disorder after the ischemic event. However, the occurrence of depression and other functional abnormalities on the first day following AIS is largely unknown. Neuroactive steroids have the capability to modulate in a positive or negative way the function of the nervous system. Changes in neuroactive steroid concentrations in plasma and nervous system have been described in degenerative diseases (Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis), autoimmune diseases (multiple sclerosis), epilepsy, and psychiatric disorders (depression and schizophrenia). In vulnerable regions such as the hippocampus and prefrontal cortex, high cortisol exposure damages the pyramidal neurons, decreases neurogenesis and impairs memory and learning. In a previous report, the investigators have demonstrated that old patients with AIS show changes in the plasma levels of cortisol and estradiol, which associate with low cognition, worse neurological status, and poor functional performance. The present report investigated changes of cortisol, brain-derived neurotrophic factor (BDNF) and nitrites (NO-2, nitric oxide soluble metabolites) after AIS. BDNF is a neurotrophin classically associated with learning and memory and negatively modulated by glucocorticoids, old age, and neurodegenerative diseases. In plasma, platelets are the major source of peripheral BDNF and levels of this neurotrophin are decreased in Alzheimer´s disease and depression. These disorders also show hypercortisolism and changes of cortisol dynamics suggesting that steroids, neurotrophins, and behavioral deficits may be functionally related. Regarding nitrites, cortisol treatment of human subjects significantly reduced plasma nitrate/nitrite concentrations. Therefore, considering that opposite changes occur in cortisol vs. BDNF and nitrites, the investigators aimed to determine in acute AIS patients (a) changes in plasma cortisol; (b) development of clinical, behavioral and functional deficits; (c) changes in plasma BDNF and nitrites, which may predict a neurotoxic effect of the excess cortisol in the ischemic nervous system.

연구 유형

관찰

등록 (실제)

40

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

60년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

확률 샘플

연구 인구

The subjects were between 60 and 90 years old, and were recruited randomly and distributed in two experimental groups: 1) a control group composed of subjects without physical or psychiatric disease, 2) an AIS group composed of subjects within the first 24 hours of the neurovascular event. The individuals were distributed in such a way that each experimental group contained 10 men and 10 women. Table 1 show the inclusion and exclusion criteria used for the AIS group.

설명

Inclusion Criteria:

  • Age between 60 and 90 years.
  • Agreeing to participate in the study.
  • Acute Ischemic Stroke of anterior vascular territory and/or posterior vascular territory whithin 24 hours of onset.
  • Nine or more points in the Glasgow Coma Scale.
  • Female patients in menopause.
  • Patients without cognitive impairment before AIS according to family reference.
  • Acceptance of the next of kin proxy in case the participant has sensory impairment.

Exclusion Criteria:

  • Age <60 or > 90 years.
  • Hemorrhagic Stroke.
  • Transient ischemic attack (TIA).
  • Acute Ischemic Stroke after 24 hours of onset.
  • Hormonal replacement therapy.
  • Immunosuppressive therapy in the last month before AIS (example corticosteroids).
  • Acute infection (Example, pneumonia, urinary tract infection).
  • Diagnosis of oncologic disease in the last month before AIS.
  • Diagnosis of endocrinologic disease in the last month before AIS.
  • Acute or long-term psychiatric illness.
  • No agreement to participate in the study.
  • Eight or less points in the Glasgow Coma Scale.
  • Female patients with menstrual cycle or in the perimenopause.
  • Patients with kidney or hepatic illness.
  • Patients with cognitive impairment before AIS.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: 케이스 컨트롤
  • 시간 관점: 유망한

코호트 및 개입

그룹/코호트
개입 / 치료
Control group
A control group composed of subjects without physical or psychiatric disease.
We observed relationship between plasma levels of cortisol and neurological, cognitive, functional and emotional outcomes in patients with acute ischemic stroke.
다른 이름들:
  • Plasma cortisol levels quantification
  • Plasma nitrites levels quantification
  • Plasma Brain Derived Neurotrophic Factor quantification
Acute Ischemic Stroke group
An AIS group composed of subjects within the first 24 hours of the neurovascular event.
We observed relationship between plasma levels of cortisol and neurological, cognitive, functional and emotional outcomes in patients with acute ischemic stroke.
다른 이름들:
  • Plasma cortisol levels quantification
  • Plasma nitrites levels quantification
  • Plasma Brain Derived Neurotrophic Factor quantification

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Neurological déficit
기간: Into 24 hours of Acute Ischemic Stroke
The neurological state during AIS was quantified by the National Institute of Health stroke scale at the time of hospitalization (NIHSS,available at http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf
Into 24 hours of Acute Ischemic Stroke

2차 결과 측정

결과 측정
측정값 설명
기간
Cognition
기간: Into 24 hours of Acute Ischemic Stroke
The cognitive test used was the Montreal Cognitive Assessment (MoCA test).
Into 24 hours of Acute Ischemic Stroke
Emotional state
기간: Into 24 hours of Acute Ischemic Stroke
Patients with AIS were evaluated on the Montgomery-Asberg depression scale (MADRS)
Into 24 hours of Acute Ischemic Stroke
Functional dependency of daily life activities
기간: Into 24 hours of Acute Ischemic Stroke
The functional state of the AIS patients was assessed by the modified Rankin scale at the time of entering the admission floor.
Into 24 hours of Acute Ischemic Stroke
Cortisol
기간: Into 24 hours of Acute Ischemic Stroke
Plasma cortisol concentration was determined by chemiluminescent microparticle immunoassay (CMIA), using Team Architect i1000, Abbott Laboratories, Middletown, USA.
Into 24 hours of Acute Ischemic Stroke
Quantification of nitrites concentration (NO-2)
기간: Into 24 hours of Acute Ischemic Stroke
Levels of NO-2, nitric oxide soluble metabolite (ON.) in water, were measured spectrophotometrically at 543 nm absorbance by the Griess reactio
Into 24 hours of Acute Ischemic Stroke
BDNF quantification in plasma
기간: Into 24 hours of Acute Ischemic Stroke
Plasma BDNF concentration was measured by enzyme-linked immunosorbent assay (ELISA)
Into 24 hours of Acute Ischemic Stroke

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Sebastian M Casas, Ph.D., MD., Hospital Militar Central Cir My ¨Dr. Cosme Argerich¨

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2016년 4월 1일

기본 완료 (실제)

2016년 12월 1일

연구 완료 (실제)

2016년 12월 1일

연구 등록 날짜

최초 제출

2017년 8월 2일

QC 기준을 충족하는 최초 제출

2017년 8월 7일

처음 게시됨 (실제)

2017년 8월 8일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2017년 8월 8일

QC 기준을 충족하는 마지막 업데이트 제출

2017년 8월 7일

마지막으로 확인됨

2017년 8월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

허혈성 뇌졸중에 대한 임상 시험

Behavioral tests에 대한 임상 시험

구독하다